Andy Weisenfeld has been an investment banker since 1989. Mr. Weisenfeld became a Partner at MTS Health Partners in January 2008, primarily responsible for the development of the life sciences and medical technology practices. Prior to joining MTS, Mr. Weisenfeld was a Managing Director in Banc of America Securities’ Corporate and Investment Banking Healthcare Group. He co-led the firm’s life sciences practice, providing capital raising and strategic advisory services to publicly traded and private companies. Before joining Bank of America in 2003, Mr. Weisenfeld was a Managing Director at JP Morgan and its predecessor company, Chase Securities, leading its Healthcare M&A business across all healthcare sectors from mid-1997 to the start of 2003. Prior to joining Chase, Mr. Weisenfeld spent over five years in the M&A Group at Merrill Lynch. Throughout his career, he has worked on a wide range of advisory transactions, including acquisitions, sale transactions, and strategic relationships.

Mr. Weisenfeld’s work in 2023 earned him the distinction of being named to Business Insider’s “Rainmakers” list, recognizing the top 20 M&A bankers who orchestrated the largest deals in North America.

Mr. Weisenfeld’s selected life sciences transactions include:

• sale of Seagen to Pfizer
• sale of Chinook Therapeutics to Novartis
• sale of CTI Biopharma to Swedish Orphan Biovitrum (SOBI)
• sale of EQRx, Inc. to Revolution Medicines
• sale of Veloxis to Asahi
• acquisition of Alder by Lundbeck
• merger of Keryx with Akebia
• sale of Colucid to Lilly
• sale of Celator to Jazz Pharmaceuticals
• Otsuka’s acquisitions of Avanir and Neurovance
• reverse merger transactions for Chinook, Neoleukin, Synta (to become Madrigal), Regado (to become Tobira), and Trimeris (to become Synageva)
• Reata’s strategic partnership with Abbott Labs
• Genzyme’s acquisition of Bioenvision
• sale of Corixa to GlaxoSmithKline
• sale of TKT to Shire
• sale of ALZA to J&J

Mr. Weisenfeld has also been responsible for many life sciences financings, including the monetization of Immunogen’s Kadcyla’s royalty and acting as advisor in the Alder, Tracon, and NuPathe IPOs.

Mr. Weisenfeld is a board member of Public Health Solutions, a significant New York-based not-for-profit. Mr. Weisenfeld is also an active alumnus of Cornell University, acting as a member of a number of bodies, including the scientific advisory committee of Weill Cornell Medical School’s Daedalus Fund for Innovation, the Cornell Dyson School’s Undergraduate Program Advisory Council and most recently the Dean’s Advisory Council of Cornell’s new Brooks School of Public Policy. Mr. Weisenfeld holds an MBA from The Wharton School at the University of Pennsylvania and a BS from Cornell University.